Scientist, Biostatistics Unit
Associate Faculty
The Cyprus Institute of Neurology and Genetics
PhD in Statistical Analyses of Genome-wide Association Studies in Breast Cancer (University of Cambridge, 2015)
MSc in Applied Statistics (University of Oxford, 2009)
BSc in Mathematics (Aristotle University of Thessaloniki, 2008)
Academic Appointments:
2017 Associate Lecturer in Statistics, UClan Cyprus (Modules Taught: Biostatistics and Epidemiology)
2015- Academic Faculty Associate, Cyprus School of Molecular Medicine
Consortia:
Breast Cancer Association Consortium (BCAC), http://bcac.ccge.medschl.cam.ac.uk/
Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), http://cimba.ccge.medschl.cam.ac.uk/
Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA), https://enigmaconsortium.org/
Dr Michailidou is a statistical genetic epidemiologist with extensive expertise in the analysis of large genetic and genomic datasets. She currently holds the post of an Associate Scientist in biostatistics at the Cyprus Institute of Neurology and Genetics (CING).
As part of her PhD and post-doctoral work, she was involved in the analyses of Genome-wide Association Studies in breast cancer. She has been one of the main statisticians for the Breast Cancer Association Consortium (BCAC) and identified more than 100 of the current known polymorphisms that are associated with breast cancer susceptibility. She has co-authored more than 100 publications in high impact journals and is a leading author of publications in Nature, Nature Genetics, Cancer Discovery, American Journal of Human Genetics and others. She has been involved in numerous and diverse biostatistical and statistical genetic projects ranging from analyses of mutation carriers in order to identify potential modifiers of risk in rare disorders to analyses of candidate genes, proteomic biomarker discovery and replication.
Current research projects include the development of polygenic risk scores, fine-mapping analyses and classification of Variants of Uncertain clinical significance (VUS) in cancer susceptibility genes. In recent years she has also been interested in the statistical and bioinformatic analyses of Next Generation Sequencing data (NGS) for diagnostics and research purposes.
Selected Publications: